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ABSTRAK 
KEBERKESANAN PENGGUNAAN NEBULIZER SALBUTAMOL SAHAJA 
BERBANOING PENGGUNAAN NEBULIZER SALBUTAMOL YANG 
OITAMBAH OENGAN ATROVENT® KE ATAS PESAKIT ASMA 01 
JABATAN KECEMASAN HUSM 
OBJEKTIF 
Objektif penyelidikan ini adalah untuk membezakan keberkesanan 
penggunaan nebulizer salbutamol dengan membandingkan penggunaan 
nebulizer salbutamol yang ditambah dengan Atrovent® ke atas pesakit 
asma di Jabatan Kecemasan. 
KAEDAH 
Penyelidikan ini dilakukan secara prospektif dan cubaan klinikal ini 
adalah secara rambang di Jabatan Kecemasan Hospital Universiti (HUSM) 
Kubang Kerian, Kelantan. Kesemua pesakit yang terpilih mestilah 
memenuhi segala syarat yang disediakan dan pesakit mestilah dalam 
keadaan serangan asthma yang akut. Pesakit yang terpilih akan 
dibahagikan kepada dua kumpulan, iaitu kumpulan pertama untuk nebulizer 
salbutamol sahaja manakala kumpulan kedua untuk nebulizer salbutamol 
yang ditambahkan dengan Atrovent®. Dos salbutamol yang digunakan 
Vlll 
adalah 5 miligram manakala Atrovent® ialah 0.5 m ilig ram. Kesemua pesakit 
yang terpilih sebenarnya adalah pesakit yang datang ke jabatan 
kecemasan yang mana kemudiannya diberikan nombor. Pesakit yang 
mendapat nombor ganjil akan ke kumpulan pertama dan yang dapat 
nombor genap akan ke kumpulan kedua. 
Penggunaan nebulizer adalah dengan menggunakan kaedah atiran 
oksigen diantara 5 - 8 liter seminit. Ukuran pembacaan meter penghembus 
(PEFR) yang ditentukan akan direkodkan yang mana ianya akan ditentukan 
pada permulaan (sebelum penggunaan nebulizer) dan juga pada minit ke 
30. Parameter klinikal yang lain juga direkodkan seperti kelajuan degupan 
jantung, tekanan darah dan kiraan pemafasan. Pemerhatian klinikaJ 
dilakukan dengan menggunakan mesin pegawasan berjenama PropaqTM. 
Kesemua data yang diperolehi akan dianalisa dengan menggunakan 
SPSS® versi 9.0 dan tahap statistik yang 'significanf jika nilai p kurang 
daripada 0.05. 
KEPUTUSAN 
73 pesakit berumur di antara 13 - 60 tahun diperolehi yang mana 
min (± SD) 31.19 (14.81) dalam kumpulan pertama dan (± SO) 28.93 
(13.85) di kumpulan kedua. Daripada 73 pesakit, 56 pesakit adalah 
termasuk dalam penyelidikan ini. Daripada jumlah pesakit yang terpilih, 26 
pesakit dalam kumpulan pertama dan 30 pesakit dalam kumpulan kedua. 
IX 
Jumlah rambang ini telah dianalisa secara statistik dan didapati ianya tidak 
dalam tahap statistik yang 'significant'. 
Dari penyelidikan ini didapati: 
1. Pembacaan permulaan meter pengukur rintangan hembusan 
(PEFR) dalam kedua-dua kumpulan tidak menunjukkan tahap 
statistik yang 'significanf (p lebih daripada 0.05). 
2. Kedua-dua kumpulan ini menunjukkan peningkatan yang berkesan 
dalam pembacaan meter pengukur rintangan hembusan dari 
permulaan pembacaan hingga ke tahap 30 minit dengan tahap p 
kurang daripada 0.05. Sila pembacaan meter pengukur rintangan 
hembusan yang di perolehi dibandingkan di antara dua kumpulan 
secara statistik, ianya tidak menunjukkan tahap yang 'significant' (p 
lebih daripada 0.05). 
3. Tidak menunjukkan tahap yang bermakna dalam jumlah kemasukan 
pesakit ke wad. 
4. Tidak menunjukkan tahap yang 'significant' dalam pembacaan 
klinikal seperti kelajuan degupan jantung, tekanan darah, kiraan 
pemafasan dan saturasi oksigen. 
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KESIMPULAN 
Dalam penyelidikan ini, keputusan yang diperolehi menunjukkan 
bahawa nebulizer salbutamol sahaja dan nebulizer salbutamol yang 
ditambah dengan Atrovent® memberikan tindak balas yang memuaskan di 
mana dilatasi salur pernafasan dan pembacaan meter pengukur rintangan 
hembusan meningkat (p kurang daripada 0.05). Bila keputusan pembacaan 
meter pengukur rintangan hembusan di bandingkan dengan kedua-dua 
kumpulan, di dapati analisa statistik tidak menunjukkan 'significanf (p lebih 
daripada 0.05). Keputusan penyelidikan akhirnya telah menunjukkan 
dengan penambahan Atrovent® atau tiada penambahannya ke dalam 
nebulizer salbutamol tidak akan memberi makna terhadap rawatan 
serangan asthma yang akut dalam 30 minit yang pertama perawatan. 
Didalam penyelidikan in; ianya telah menunjukkan bahawa tiada 
keberkesanaan kJinikal terhadap penambahan Atrovent® bersama 
salbutamol dengan menggunakan nebulizer terutamanya dalam 30 minit 
yang pertama di jabatan kecemasan. Walaupun keputusan penyelidikan 
menunjukkan bahawa penambahan Atrovent® tiada kesan pada 30 minit 
pertama, seseorang tidak sepatutnya membuat kesimpulan yang mana 
penambahan Atrovent® dengan salbutamol ini tiada peranan langsung 
dalam rawatan asthma yang akut. 
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ABSTRACT 
THE EFFECTIVENESS OF SALBUTAMOL NEBULIZER ALONE VERSUS 
SALBUTAMOL NEBULIZER WITH ADDED ATROVENT® IN ASTHMATIC 
PATIENTS AT EMERGENCY DEPARTMENT HUSM 
OBJECTIVE 
The objective of this study is to compare the effectiveness of 
nebulized salbutamol alone versus nebulized salbutamol combined with 
ipratropium bromide (Atrovent®) on asthmatic patients presenting to the 
emergency department. 
METHODS 
The study is a prospective, single blind, randomized clinical trial 
conducted at the emergency department, University Hospital (Hospital 
Universiti Sains Malaysia) Kubang Kerian, Kelantan. Patients were included 
in the study if they fulfilled the inclusion criteria and presented with acute 
exacerbation of asthma. The patients were divided into two groups, 
nebulizer salbutamol alone as group 1 and nebulizer salbutamol with 
Atrovent® as group 2. The dose used was 5 milligrams for salbutamol and 
0.5 milligrams for ipratropium bromide (Atrovent®). Patients were selected 
in either group by identification on presentation at emergency department 
xii 
with numbers, patients who received odd numbers belong to group 1 and 
even numbers belong to group 2. 
Nebulization was given by oxygen drive at a flow of 5 - 8 litres per 
minute and peak expiratory flow rate measurements were recorded at 
baseline (before nebulizer) and after the first 30 minutes. Other parameters 
taken for clinical evaluation include heart rate, oxygen saturation, blood 
pressure and respiratory rate using PropaqTM brand monitor. 
The data was analysed using SPSS® version 9.0 with statistical 
significance taken as p value less than 0.05. 
RESULTS 
A total of 73 patients aged 13 - 60 years old were selected with the 
mean (+ SO) of 31.19 (14.81) in group one and (± SO) of 28.93 (13.85) in 
group two. Of these, 56 patients were included in the study and the 
remaining 13 patients were excluded as they did not fulfil the criteria. There 
were 26 patients in group 1 and 30 patients in group 2 of which 30 were 
male patients and 26 were female patients. Statistically, the distribution of 
male and female did not show any significant difference. 
XIl1 
From this study it was found that: 
1. Peak expiratory flow rate at baseline in both groups was not 
statistically different (p value more than 0.05). 
2. Both groups study have shown that it improved significantly in peak 
expiratory flow rate from baseline to the first 30 minutes of therapy 
with p value less than 0.05, but the peak expiratory flow rate 
statistically is not significant when the two groups were compared 
together (p value more than 0.05). 
3. No Significant difference in the number of patients that were admitted 
to ward. 
4. No significant difference in the clinical parameter of heart rate. blood 
pressure, oxygen saturation and respiratory rate statistically. 
CONCLUSION 
In this study, the data showed that nebulizer salbutamol alone and 
nebulizer salbutamol combined with Atrovent® both resulted in 
bronchodilatation and significant improvements in measured peak 
expiratory flow rate (p value less than 0.05). However, when these results 
were compared statistically between the two groups, it was not of statistical 
significance (p value more than 0.05). The results showed that adding or 
not adding Atrovent® had no significance in the treatment of acute 
exacerbation of bronchial asthma in the first 30 minutes of nebulizer 
therapy. 
XlV 
This study has shown no benefit to the routine use of a combination 
solution containing ipratropium bromide and salbutamol when compared 
with salbutamol alone in the first 30 minutes of therapy. In spite of this. one 
should not conclude that combination therapy has no role in the treatment 
of acute asthma. 
xv 
INTRODUCTION 1 
Asthma is a common disease among adults and children. It is well 
known that asthma is a worldwide disease, with alarmingly high rates of 
morbidity and mortality. In Malaysia, it is estimated that around two million 
people have been diagnosed with asthma. Therefore, asthma is a common 
disease among adults and they can present as a medical emergency, and 
the number of patients turning up at emergency department will be 
increased. Malaysian figures have shown an increasing trend of asthma 
patients attending emergency department that is about 10 percent of the 
Malaysian population who seek treatment for acute medical illness at 
emergency department. Medical emergency accounts for about 55 percent 
of all emergency cases, with acute asthma being the most common medical 
emergency seen, accounting for about 50 to 60 percent of cases seen per 
day. Several studies have shown that acute asthma is indeed the 
commonest medical emergency seen in most of the emergency department 
all over the nation, representing about 10 to 14 percent of the total number 
of patients seen daily. This has proven that prompt medical attention is 
mandatory towards a patient's care especially in handling acute medical 
illness like asthma in the emergency department. 
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Management of asthma in emergency department is crucial and 
need special attention because improper management will lead to over-
loading of patients in emergency department and in-patient wards. The 
main goal of asthma management in emergency department is to relieve 
the acute exacerbation and prevent further deterioration. The common 
treatment of acute exacerbation of asthma in emergency department is by 
inhalation especially by nebulizer with bronchodilator agents. The choice 
and effectiveness of bronchodilator agents are important in the first step in 
the acute exacerbation of asthma management. The purpose of this study 
is to see the effectiveness of the bronchodilator agents used in emergency 
department to solve the problem of too many patients in a crowded asthma 
bay and to avoid unnecessary admissions to the ward. 
The purpose of the study is to assess the effectiveness of different 
bronchodilator agents given by nebulizer in the emergency department. In 
this way. the choice of agents used in nebulizer therapy will help to reduce 
the length of stay in the emergency department. The question is which 
bronchodilator agents are ideal to serve this purpose. 
The topic of this study was chosen based on other studies done at 
different centres. The study is specifically designed for the population of 
Kota Bharu. A number of studies have looked into this issue, with conflicting 
results. Many practicing doctors believe that the combination of AtrovenfD 
(Ipratropium bromide) with salbutamol is the best therapy in initial asthma 
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management within the emergency department. even though research 
evidence is lacking to support one regime over the other. 
The topic of this study is to evaluate the effectiveness of the 
nebulizer salbutamol alone versus nebulizer salbutamol combined with 
Atrovent® in treating asthmatic patients presenting to the emergency 
department. We also wanted to see the difference in effectiveness of the 
nebulizer given in an acute setting in the first 30 minutes of treatment. It is 
known that salbutamol alone provides good bronchodilatation; however. in 
combination with Atroven~. it is not clear if there is any additional 
bronchodilator effect; and whether this additional effect, if any, is additive or 
synergistic in nature. In other words, we aim to evaluate the effect of 
combined AtrovenfDwith Salbutamol in the early therapy of acute asthma. 
This study had its limitations, which had to be overcomed. The study 
was been done at University Hospital (Hospital Universiti Sains Malaysia) 
Kubang Kerian. In any emergency department, the first limitation is 
manpower. It is a well-known fact that within any emergency department, 
workload does not conform to any fixed rules nor fixed timings. Patient care 
would always take precedence. Not only was problems encountered 
regarding manpower in conducting this study, many patients sometimes did 
not give full cooperation towards the study. Many requested to go back 
early after feeling better following treatment of nebulizers and thus the 
duration of the study was affected drastically. The initial aim to monitor the 
patients half-hourly, for at least 90 minutes of their initial nebulizer therapy 
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was not possible due to this reason. Due largely to this fact. we were only 
able to monitor our patients for the initial 30 minutes of therapy. Another 
limitation was the attitude of patients toward the study. This study gave 
patients the impression that they were part of an experiment (during the 
study itself). In the end, many patients refused to participate in the study. 
The number of the patients involved in the study was also affected. The 
patients involved were not pre-selected and most of them presented 
themselves as cases of acute exacerbation to the emergency department. 
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LITERATURE REVIEW 2 
2.1 DEFINITION 
Asthma is defined as a condition of airway hypersensitivity and 
reversible airway obstruction that results in intermittent symptoms of 
wheezing, dyspnoea, and cough. However, asthma is more than a simple 
reversible airway obstruction (Busse WW et aI, 1993). 
Previously, it was believed that asthma referred to almost any sort of 
difficulty in breathing, especially if it is paroxysmal or episodic. Later in the 
new recommendations, additions were made related to difficulty in 
breathing and associations with wheezing. In 1958, a Ciba Foundation 
Guest Symposium suggested: Asthma refers to the condition of subjects 
with widespread narrowing of the bronchial airways, which change in 
severity over the short periods of time either spontaneously or under 
treatment, and it is not due to cardiovascular disease. The clinical 
characteristics are abnormal breathlessness, which may be paroxysmal or 
persistent, wheezing, and in most cases is relieved by bronchodilator drugs 
(Ciba Foundation, 1959). 
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In 1962, The Committee on Diagnostic Standard of the America 
Thoracic Society suggested: Asthma is a disease characterized by an 
increased responsiveness of the trachea and bronchi to a variety of stimuli 
and manifested by widespread naffowing of the airways that changes in 
severity either spontaneously or as a result of therapy_ Asthmal as defined 
may occur in subjects with other bronchopulmonary or cardiovascular 
diseases, but in these instances the airway obstruction is not causally 
related to these diseases (American Thoracic Society Committee on 
Diagnostic Standards, 1962). 
Current thinking and new research developments have changed the 
definition of asthma. Asthma is characterized also by paroxysmal 
spasmodic narrowing of the bronchial airways due to inflammation of the 
bronchi and bronchial smooth muscle contractions. The inflammation 
component is central to the pathogenesis of symptoms, bronchoconstriction 
and airway hyper-responsiveness leading to dyspnoea and wheezing. Also 
inflammation can be characterized by oedema, infiltration with inflammatory 
cells especially eosinophils, hypertrophy of glands, smooth muscle and 
damaged epithelium. These will result in the state of hyper-responsiveness 
where airways narrow easily in respond to wide range of stimuli (Holgate 
ST and Finnerty JP, 1988), which is presented clinically as sign, and 
symptom of coughing, wheezing, chest tightness and shortness of breath. 
They are often worst at night and the symptoms are called 'attack '- The 
airway narrowing is usually reversible but in some patients with chronic 
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asthma the inflammation may lead to irreversible airway obstruction (Roche 
WR et ai, 1989). 
A working definition of asthma should include underlying airway 
inflammation with its physiological correlation and bronchial hyper-
responsiveness [figure 2.1]. The clinician, physiologist, immunologist, and 
pathologist all may have different perspectives on asthma definition. The 
merging of this different perspective into an acceptable definition of asthma 
has begun to occur and is important for more specific and effective 
treatment of this disease. 
Based on current knowledge, a working definition of asthma is: 
Asthma is a chronic inflammatory disorder of the airways in which many 
cells and cellular elements play a vital role particularly, mast cells, 
eosinophils, T-Iymphocytes, macrophages, neutrophils, and epithelial cells. 
In susceptible individuals, this inflammation causes recurrent episodes of 
wheezing, breathlessness, chest tightness, and coughing, parlicularly at 
night or in the early morning. These episodes are usually associated with 
widespread but variable airflow obstruction that is often reversible either 
spontaneously or with treatment. The inflammation also causes an 
associated increase in the existing bronchial hyper-responsiveness to a 
variety of stimuli (National Heart, Lung and Blood Institute, 1995). 
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EnvironmenI risk factors (causes) 
INFLAMMATION 
Airway 
Hyper responsiveness 
Airflow 
a::::=:=r==::::::--:---> Obstruction 
Precipitants 
Symptoms 
Adapted from Stephen T. Holgate. M.D .. D.Sc. 
Figure 2.1: Mechanisms Underlying the Definition of Asthma 
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2.2 PATHOPHYSIOLOGY OF ASTHMA 
Asthma, whatever the severity, is a chronic inflammatory disorder of 
the airways. This has implications for the diagnosis, management, and 
potential prevention of the disease. Pathogenesis of asthma is related to 
each other, which are divided into three components, that is: 
1. Airway inflammation 
2. Airway obstruction 
3. Airway hyper-responsiveness 
2.2.1 Airway inflammation 
The airways of asthma patient are infiltrated by a number of different 
inflammatory cells, which then cause complex interactions resulting in 
epithelial disruption and mucosal oedema. An initial trigger in asthma may 
cause the release of inflammatory mediators from the bronchial mast cells, 
macrophages, and epithelial celfs. These substances cause the directed 
migration and activation of an inflammatory infiltrate composed 
predominantly of eosinophils and neutrophils. Chemical substances like 
leukotrienes are then released and they will further attract cellular infiltrates. 
This event will produce epithelial injury, abnormalities in neural mechanism, 
and increase in airway smooth muscle responsiveness and airflow 
obstruction. 
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Epithelial injury can lead to increased permeability and sensitivity to 
inhaled allergens, irritants, and inflammatory mediators. Furthermore, 
transudation of fluid and reduced clearance of inflammatory substances and 
respiratory secretions occur with disruptions of epithelium mucocilliary 
mechanism. This process may lead to chronic irritation of the airways. The 
illustrated diagram (figure 2.2) will show the event of the inflammation that 
occurs in asthma patient, which contributes to airway inflammation (Busse 
et ai, 1993). 
2.2.3 Ai rway obstruction 
Airflow limitation in asthma is recurrent and caused by a variety of 
changes in the airway. These include: 
1. Acute bronchoconstriction. 
Allergen-induced acute bronchoconstriction results from an 
immunoglobulin-E dependent release of mediators from the mast 
cells that includes histamine, tryptase, leukotrienes, and 
prostaglandin (Marshall and Bienenstock, 1994), which directly 
contract the airway smooth muscles. Aspirin and other non-
steroidal anti-inflammatory drug can also cause acute airflow 
obstruction in some patients and evidence indicates that non-
Immunoglobulin-E dependent response also involves mediator 
release from airway cells (Fisher et ai, 1994). 
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MACRO PHAGES 
;1 
Proinflammatory 
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MACROPHAGES 
1 
::::::>- Chronic 
Figure 2.2: CELLULAR MECHANISMS INVOLVED IN AIRWAY 
INFLAMMATION 
(James and Kay, 1995) 
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Other stimuli including exercise, cold air and irritants can 
cause acute airflow obstructions. This mechanism is unknown but 
the intensity of the response appears related to underlying airway 
inflammation (Busse et ai, 1993). Stress to can play a role in 
precipitating exacerbation of asthma although the exact 
mechanism is still unclear. It is postulated that this involves 
enhanced generation of proinflammatory cytokines (Friedman et 
ai, 1994). 
2. Airway oedema 
Airway wall oedema, even without smooth muscle contraction 
or bronchoconstriction, limits airflow in asthma. Increased micro-
vascular permeability and leakage caused by the released 
mediators also contribute to mucosal thickening and swelling of 
the airway wall. As a consequence, swelling of the airway wall 
causes the airway to become more rigid and interferes with 
airflow. 
3. Chronic mucus plugs fonnation. 
In severe intractable asthma, airflow limitation is often 
present. In part, this change may arise as a consequence of 
mucus secretion and the formation of inspissated mucus plug. 
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4. Airway remodelling. 
In some patients with asthma, airflow limitation may be only 
partially reversible. The aetiology of this component is not as well 
studied as other features of asthma but may relate to structural 
changes in the airway matrix that may accompany longstanding 
and severe airway inflammation. There is evidence that a main 
histological feature of asthma in some patient is an alteration in 
the amount and composition of the extra cellular matrix in the 
airway wall (Djukanovic et ai, 1990; Laitinen and Laitinen, 1994). 
As a consequence of these changes, airway obstruction may be 
persistent and not responsive to treatment. Regulation of this 
repair and remodelling process is not well established, but the 
process of repair and its regulation are likely to be key events in 
explaining the persistent nature of the disease and limitation of 
response to therapy. The above postulation suggests a rationale 
for early intervention with anti-inflammatory therapy. 
2.2.4 Airway hyper-responsiveness 
An important feature of asthma is an exaggerated 
bronchoconstriction in response to wide variety of stimuli. Airway hyper-
responsiveness leads to clinical symptoms of wheezing and dyspnoea after 
exposure to allergens, environmental irritants, viral infections, cold air, or 
exercise. Research indicates that airway hyper-responsiveness is important 
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in the pathogenesis of asthma and that the level of airway responsiveness 
usually correlates with the clinical severity of asthma. 
The importance of the airway inflammatory response to airway 
hyper-responsiveness is substantiated by several observations. First, 
airway markers of inflammation correlate with bronchial hyper-
responsiveness. Second, treatment of asthma and modification of airway 
inflammatory markers not only reduce symptoms but also diminish airway 
responsiveness. Some investigators have shown that although anti-
inflammation therapy reduced airway hyper-responsiveness, it did not 
eradicate it. A small study found that control of airway inflammation did not 
control bronchial hyper-responsiveness (Lundgren et ai, 1988). From this, it 
may be concluded that some other factor, in addition to inflammation, 
contributes to airway hyper-responsiveness. 
14 
2.3 DIAGNOSIS 
Diagnosing asthma is the first step towards effective treatment. 
Studies show that up to half of all asthmatics do not receive proper 
treatment because they do not recognise the signs, and so they suffer 
needlessly. However, there are also cases where people have· been 
misdiagnosed with asthma and received unnecessary treatment This is 
particularly common in children who have a greater tendency to wheeze 
because their airways are small and their immune response involves mucus 
as a major factor. Two-thirds of infants under one year old who wheeze with 
respiratory infections ultimately do not develop asthma. 
Making a correct diagnosis is extremely important, so as correct 
treatment can then be followed. DiagnOSis guideline is necessary and the 
key indicators are listed below. 
2.3.1 Key Indicators for Diagnosing Asthma 
1. Wheezing is a high-pitched whistling sound that occurs when 
breathing out especially in children (A normal chest examination does not 
exclude asthma) and history of any of the following: 
(i) Cough, worse particularly at night 
(ii) Recurrent wheeze 
(iii)Recurrent difficulty in breathing 
15 
(iv)Recurrent chest tightness 
Note: Eczema, hay fever, or family histories of asthma or atopic diseases 
are often associated with asthma, but they are not key indicators. 
2. Symptoms may occur or worsen at night, awakening the patient. 
Symptoms that occur or worsen in the presence of: 
(i) Exercise 
(ii) Viral infection 
(iii) Exposure to animals (especially with fur) 
(iv) Exposure to domestic dust mites (in mattresses, pillow, upholstered 
furnitu re, ca rpets) 
(v) Smoke (tobacco, wood) 
(vi) Pollen 
(vi) Changes in temperature 
(vii) Strong emotional expression (laughing or crying hard) 
(viii) Aerosol chemical 
3. Revisable and variable airflow limitation as measured by using a 
peak expiratory flow meter in any of the following way: 
(i) Peak expiratory flow rate increased more than 15 percent at least 
15 to 20 minutes after inhalation of a short acting beta-2 agonist. or 
(ii) Peak expiratory flow rate varies more than 20 percent from the 
morning measurement upon arising. to another measurement 12 
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hours later in patients on bronchodilator therapy (more than 10 
percent in patients who are not on bronchodilator therapy), or 
(iii)Peak expiratory flow rate decreases more than 15 percent after 6 
minutes of running or exercise. 
4. Diagnostic challenges include the following: 
(i) Young children whose primary symptom is cough or who wheeze 
with respiratory infections are often misdiagnosed as having 
bronchitis or pneumonia (including acute respiratory disease - ARI) 
and those ineffectively treated with antibiotics or cough 
suppressants. Treatment with asthma medication can be beneficial 
and diagnostic. 
(ii) Asthma should be considered if the patient's colds repeatedly "go 
to the chest" or take more than 10 days to clear up, or if the patient 
improves when asthma medication is given. 
(iii)Tobacco smokers and elderly patients frequently suffer from 
chronic obstructive pulmonary disease with symptoms similar to 
asthma. Yet they may have asthma and may benefit from 
treatment. Improvement in peak expiratory flow rate after asthma 
treatment is diagnostic. 
(iv)Workers who are exposed to inhalant chemicals or allergens in the 
workplace can develop asthma and may be misdiagnosed as 
having chronic bronchitis or chronic obstructive pulmonary disease. 
Early recognition (Peak expiratory flow rate measurements at work 
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and home), strict avoidance of further exposure, and early 
treatment are essential. 
These indicators are useful in diagnosing asthma and if any of the 
indicators are present, the patients can be considered asthmatic. 
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2.4 MANAGEMENT OF ASTHMA 
The aims of management in asthma can be divided into: 
i. to recognize asthma 
ii. to abolish symptoms (relieve respiratory distress) 
iii. to restore normal or best lung function as soon as 
possible 
iv. to reduce morbidity and prevent mortality 
The management of asthma depends on how we approach and 
educate asthmatic patients. Other important steps that are required in 
managing asthma are avoidance of precipitating factors and finally, drug 
therapy. These drugs are bronchodilators and anti-inflammatory drugs, 
commonly used in the emergency department especially for the relief of 
symptoms in the acute attack. Much research has been done regarding the 
efficacy of bronchodilators used in an acute attack and many researchers 
have analysed and compared the effectiveness of different bronchodilators 
either used alone or in combination. 
2.5 Bronchodilators of beta adrenergic 
The initial management of acute asthma exacerbation in children and 
adult in the setting of an emergency department focuses on the rapid relief 
of bronchospasm with inhaled or nebulized bronchodilators. 8eta-2 agonists 
are the most effective of the bronchodilators owing to their rapid onset of 
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action and the extent of achieved bronchodilatation (Sears MR, 1992). 
Anticholinergic agents, such as ipratropium bromide (Atrovenf) and 
atropine sulphate, have a slower onset of action and weaker 
bronchodilating effect than beta-2 agonists but may relieve cholinergic 
bronchomotor tone and decrease mucosal oedema and secretions (Gross 
NJ,1988). 
Beta-2 agonists 
These drugs are the most effective bronchodilators available. The 
beta-2 agonists are the fastest and most efficacious medication to help 
alleviate bronchospasm in the acute asthmatic and are clearly the treatment 
of choice. Beta-2 agonists are catecholamine derivatives that act via an 
accumulation of cyclic AMP in the cells thus causing relaxation. They 
should be considered the main therapeutic intervention for the asthmatic 
patient. While the beta-2 agonists relax bronchial smooth muscle, they also 
help decrease bronchospasm and constriction, and help inhibit the release 
of inflammatory mediators. Additionally, they appear to increase ciliary's 
movement. They are several ways that these agents can be administered 
including oral, subcutaneous, via metered-dose inhalers, and via nebulizer. 
The oral route is less useful in acute situations and the most 
common route in the emergency department is via inhalation. They are safe 
drugs with few side-effects when taken by inhalation or nebulizer. The 
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therapeutic effect is felt within minutes of inhalation. The main side-effects 
are tremor and tachycardia. Examples of inhaled or nebulized beta-2 
agonist are salbutamol. terbutaline, fenoterol. salmeterol. 
The effect of this drug on the bronchodilatation is dose-dependent, 
which larger doses result in a more sustained effect (Barnes PJ and Pride 
NS, 1983). Asthmatic patients usually show the largest response to beta-2 
agonist but the magnitude of effect depends on pre-treatment airway 
calibre, dose, route, and method of administration. 
Selective beta-2 agonists given by metered-dose-inhalers or in the 
nebulized form are the bronchodilators of choice in patients with asthma 
and other forms of reversible airway obstruction in maintenance therapy or 
in acute attack. The need for treatment and its effects should be monitored 
by measurements of peak expiratory flow rate or force expiratory volume in 
one second (Spirometry). The monitoring of asthma patients after treatment 
by using peak expiratory flow rate is the best way to see the improvement 
and the assess the need for further intervention and proper follow-up as 
out-patients or in-ward patients. 
In severe cases of asthma, a subcutaneous form of beta-adrenergic 
therapy may be appropriate. Generally, the subcutaneous route do not offer 
any advantage over the inhaled route unless the patient is unable to take a 
nebulizer or has not responded to inhaled medication. Thus, patients with 
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altered mental status, or those in extremis, may be given subcutaneous 
doses of adrenaline, Ventolin®, or Terbutaline®. Obviously, in older patients 
the risks of giving these medications must be weighed against the 
possibility of inducing dysrhythmias or myocardial ischaemia. If a pregnant 
patient is being treated, terbutaline is a better choice, as adrenaline has 
been associated with birth defects. The dose of terbutaline is 0.25 
milligrams (up to 0.5 milligrams) in adults. In critically-ill patients, 
intravenous beta-agonists can be considered if all other measures have 
failed. 
The beta-2 adrenergic receptors 
Adrenergic receptors are classified into beta-1, beta-2, and beta-3 
receptors. In the lung, there are beta-1 and beta-2 receptors present and 
the bronchodilator action is mainly mediated via the beta-2 receptor. These 
beta-2 agonists in the lung produce their effect by interaction with specific 
beta-2 adrenergic receptors located in the plasma membrane of virtually all 
types of cell. The receptor consists of the protein that traverses the cell 
membrane seven times, forming three extra cellular, and three intracellular 
loops. Binding of the beta-2 agonists will activate cyclic-AMP, the 
intracellular second messanger, ultimately producing the physiological 
response that leads to bronchodilatation. A characteristic of many 
membrane-associated receptors, including beta-2 adrenergic receptors, is 
desensitisation after high dose or repeated exposure to the agonists. After 
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prolonged exposure, the number of receptors in the plasma membrane is 
reduced, due to decreased production of the messenger RNA for the 
receptors (down regulation) (Hadcock JR and Malborn NB, 1988). Up 
regulation of the receptor occurs as a result of increased production of 
messenger RNA. This is due to an increase in the transcription of the gene 
for the receptor, which is stimulated by glucocorticoids and thyroid 
hormones. Other non-bronchodilators functions of the beta-2 adrenergic 
agonist include: enhanced mucocilliary clearance, inhibition of cholinergic 
neurotransmission, suppression of micro-vascular leakage, inhibition of 
mediator release from mast cells and basophils, and inhibition of release of 
mediators from other inflammatory cells. 
Routes of administration 
8eta-2 adrenergic bronchodilators can be administered orally, by 
inhalation, subcutaneous or intravenous injection. The inhalation route is 
preferred almost without exception because the side-effects are fewer for 
any given degree of bronchodilatation. Inhalation is as effective as 
parenteral administration for treating acute, severe attacks of asthma in 
most patients, although some who have severe bronchial obstruction may 
benefit initially from parenteral therapy. 
Oral preparation still has some role in the treatment of children too 
young to use a metered-<tose inhaler conveniently. Sustained-release oral 
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preparations reduce nocturnal asthma, but they are not as effective for this 
purpose as the long acting inhaled beta-2 adrenergic agonists. 
The use of nebulizer to deliver bronchodilators was formerly the 
standard practice for young children, in the emergency department 
treatment of patients with acute, severe asthma and for the treatment of 
hospitalised patient. All these indications have been challenged, where the 
beta-2 adrenergic agonist therapy delivered under supervision via a 
metered-dose inhaler with a spacer device is as effective in the emergency 
department setting as therapy with the nebulizer for both adults and 
children. In hospitalised patients, therapy with metered.<Jose inhalers is as 
effective as nebulizer treatments and results in considerable financial 
savings. Even in small children, the nebulizer may be replaced by metered-
dose-inhalers with a spacer device and an attached mask. 
Potential adverse reaction to beta-2 ad renergic agonist 
Adverse reactions of the beta-2 adrenergic can be divided into those 
that result from the expected pharmacological actions of the drugs and 
those that could not be predicted from these properties. 
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